<DOC>
	<DOC>NCT01467271</DOC>
	<brief_summary>The main purpose of this study is to prospectively estimate the incidence of NSF in patients with moderate to severe renal impairment after administration of DOTAREM®</brief_summary>
	<brief_title>Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration</brief_title>
	<detailed_description>All patients will be followed up during 2 years after DOTAREM® administration to collect data on any suspected NSF or NSF related symptoms</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Patients with moderate to severe and end stage renal impairment or dialysis, scheduled for a contrast enhanced MRI with DOTAREM Patient who has received a Gadolinium Based Contrast Agent within the past 12 months prior to inclusion in this study except if the GBCA received is Dotarem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>